Spinal muscular atrophy type 1 (SMA type 1) is a rare inherited neuromuscular disorder that usually becomes apparent during the first six months of life. It primarily damages motor neuronsthe nerve cells responsible for telling muscles to move. As those nerve cells are lost, babies develop progressive muscle weakness that can affect head control, movement, swallowing, feeding, coughing, and breathing.
For decades, SMA type 1 was associated with an extremely poor prognosis. That history still appears prominently in older medical descriptions, which can make an internet search feel like opening the world’s least reassuring fortune cookie. Fortunately, the story has changed dramatically. Newborn screening, genetic testing, gene-targeted medications, and modern respiratory and nutritional support have transformed what clinicians can offer children with SMA. Early treatmentespecially before substantial weakness developscan produce outcomes that would have been extraordinary only a decade ago.
What is spinal muscular atrophy type 1?
Spinal muscular atrophy is a group of genetic disorders involving degeneration of lower motor neurons in the spinal cord and brainstem. Type 1, historically called Werdnig-Hoffmann disease or infantile-onset SMA, is generally the most common severe childhood form.
Symptoms of SMA type 1 usually begin before 6 months of age. Traditionally, infants with untreated type 1 SMA do not achieve the developmental milestone of sitting independently. However, the old milestone-based classification system has become less tidy in the treatment era because babies treated very early may achieve skills that historically were not expected for their SMA subtype.
SMA affects voluntary skeletal muscles rather than a baby’s intelligence. A child with severe physical weakness may remain socially alert and cognitively engaged. This distinction matters: weak muscles do not mean a weak mind.
What causes SMA type 1?
Most cases of SMA type 1 are caused by harmful changes affecting both copies of a gene called SMN1, short for survival motor neuron 1. This gene normally provides instructions for producing survival motor neuron, or SMN, protein.
Motor neurons depend on adequate SMN protein to survive and function properly. When the body produces too little of it, motor neurons progressively deteriorate. Muscles then receive fewer signals from the nervous system, leading to weakness and muscle atrophy.
The important role of SMN2
Humans also possess a closely related backup gene called SMN2. Unfortunately, SMN2 is a rather inefficient understudy. Most of the protein produced from it is shortened and nonfunctional, although a smaller percentage is full-length functional SMN protein.
In general, having more copies of SMN2 means the body can produce more functional SMN protein and is associated with a less severe SMA phenotype. Infants with type 1 frequently have relatively few SMN2 copies, although SMN2 copy number cannot perfectly predict how an individual child will develop.
How is SMA type 1 inherited?
Classic 5q spinal muscular atrophy follows an autosomal recessive inheritance pattern. Usually, an affected child receives one nonworking SMN1 gene copy from each parent.
Parents who carry one altered copy generally have no SMA symptoms themselves. When both parents are carriers, each pregnancy typically carries:
- a 25% chance that the child will have SMA,
- a 50% chance that the child will be an unaffected carrier, and
- a 25% chance that the child will inherit two working copies.
Carrier frequency is relatively high, estimated by the American College of Obstetricians and Gynecologists at roughly 1 in 40 to 1 in 60 people in many populations. Carrier screening can therefore be useful before or during pregnancy.
Symptoms of spinal muscular atrophy type 1
The earliest clues may be subtle. Parents sometimes notice that their baby seems unusually floppy, does not move the legs as vigorously as expected, or struggles to lift the head during tummy time.
Muscle weakness and low muscle tone
A hallmark sign is hypotonia, commonly described as decreased muscle tone or a “floppy baby.” Weakness is generally symmetric and tends to affect muscles near the center of the body more severely.
Possible signs include:
- poor head control,
- difficulty lifting the head during tummy time,
- reduced spontaneous arm and leg movement,
- legs that appear weaker than the arms,
- difficulty rolling or reaching expected motor milestones,
- a weak cry, and
- small muscle twitches, including tongue fasciculations in some infants.
Without effective early treatment, a baby with classic SMA type 1 generally would not achieve independent sitting.
Feeding and swallowing problems
Weakness may involve muscles needed for sucking and swallowing. Feeding can therefore become tiring, slow, or unsafe.
Signs that deserve medical attention include coughing or choking during feeds, difficulty coordinating sucking and swallowing, poor weight gain, long feeding sessions, or repeated respiratory infections that could potentially be associated with aspiration.
A swallowing evaluation may be recommended. Some children require changes in food consistency or temporary or long-term tube feeding to provide adequate nutrition safely.
Breathing problems
Respiratory muscle weakness is among the most serious consequences of SMA type 1. Babies may have difficulty producing a strong cough and clearing mucus. Their breathing pattern can also become distinctive because weakened muscles between the ribs cause greater reliance on the diaphragm.
Respiratory illnesses that might be merely annoying to another baby can become much more serious for a child with SMA. For this reason, respiratory specialists are frequently part of the multidisciplinary SMA team.
How doctors diagnose SMA type 1
Newborn screening
SMA has become part of newborn screening programs across the United States. Screening generally uses blood collected from the baby’s heel to look for the common genetic abnormality involving exon 7 of SMN1.
Newborn screening has changed SMA care because an affected child may now be identified before obvious weakness appears. That creates a crucial opportunity to begin treatment while more motor neurons are still functioning.
No screening test catches every possible genetic variant, however. A small percentage of patients have SMN1 changes that require more detailed sequencing. Therefore, concerning symptoms still deserve evaluation even after an apparently normal newborn screen.
Diagnostic genetic testing
If screening is positive or symptoms suggest SMA, diagnostic genetic testing can confirm abnormalities in SMN1. Testing frequently also determines SMN2 copy number because this information helps clinicians assess likely disease severity and make time-sensitive treatment decisions.
Before modern molecular testing became widely available, electromyography and muscle biopsy played a larger diagnostic role. They may still occasionally be useful when the diagnosis remains uncertain, but genetic testing has made invasive diagnostic procedures far less common.
Why early treatment matters so much
Motor neurons that have already been lost cannot simply be switched back on. Consequently, SMA treatment is unusually time-sensitive.
Research comparing infants identified through newborn screening with children diagnosed after symptoms developed has consistently shown better motor outcomes when disease-modifying therapy begins earlier. In one multicenter cohort of infants treated by six weeks of age, every child included in the reported analysis eventually achieved independent sitting, although outcomes still differed according to SMN2 copy number and whether symptoms had already appeared.
That does not mean every presymptomatically treated child will have typical development. SMA remains biologically variable. But the evidence has shifted the clinical mindset from “wait for symptoms” to something much closer to “every day matters.”
Current treatments for SMA type 1
Modern SMA therapy targets the underlying shortage of functional SMN protein rather than merely treating complications. Several FDA-approved disease-modifying approaches are available in the United States.
Nusinersen (Spinraza)
Nusinersen is an antisense oligonucleotide that modifies processing of SMN2 messenger RNA so that the gene produces more full-length functional SMN protein.
It is administered directly into the cerebrospinal fluid through an intrathecal injection. Treatment includes loading doses followed by ongoing maintenance dosing. As of 2026, FDA labeling includes both standard and higher-dose regimens for pediatric and adult SMA patients.
Onasemnogene abeparvovec-xioi (Zolgensma)
Zolgensma is a one-time intravenous gene-replacement therapy designed to deliver a functional copy of the SMN gene to motor neurons. In the United States, it is indicated for children younger than 2 years who have SMA with bi-allelic SMN1 mutations.
Gene therapy requires extensive medical screening and follow-up because potentially serious adverse effects can occur. Families considering it should discuss eligibility, laboratory monitoring, immune considerations, and risks with an experienced neuromuscular team.
Risdiplam (Evrysdi)
Risdiplam is an oral SMN2 splicing modifier that increases production of functional SMN protein. FDA labeling covers pediatric and adult patients, including infants younger than 2 months. It is taken daily, with dosing determined by age and body weight.
A newer gene-therapy option for patients age 2 and older
The SMA treatment landscape continues to evolve. In November 2025, the FDA approved Itvisma (onasemnogene abeparvovec-brve), an intrathecal gene therapy for pediatric and adult SMA patients age 2 years and older with a confirmed SMN1 mutation. It is not an infant treatment, but it is relevant to the increasingly large population of people with early-onset SMA surviving beyond infancy and childhood.
Which therapy is appropriate cannot be determined from the SMA type alone. Age, previous treatment, symptoms, liver health, anatomy, antibody status, clinical history, medication risks, and other factors may influence treatment planning.
Supportive care is still essential
Disease-modifying drugs have transformed SMA, but medication is only one piece of treatment. Children commonly benefit from care coordinated across several specialties.
Respiratory care
Respiratory management may involve assisted coughing, airway-clearance techniques, suction equipment, monitoring during sleep, or noninvasive ventilation. Plans are individualized according to respiratory strength and symptoms.
Nutrition and swallowing support
Dietitians and feeding specialists can help ensure adequate calories, hydration, and safe swallowing. A feeding tube may be considered when oral feeding is unsafe or insufficient.
Physical and occupational therapy
Therapy focuses on mobility, positioning, comfort, range of motion, and helping children make the most of their available strength. The goal is not to exhaust weak muscles with heroic gym sessions worthy of an action-movie montage; it is to support function intelligently and safely.
Orthopedic monitoring
Long-term muscle weakness can contribute to contractures, hip problems, chest-wall changes, and scoliosis. Orthopedic monitoring remains important even for children who respond well to disease-modifying therapy because newer treatment outcomes do not necessarily eliminate all musculoskeletal complications.
What is the outlook for babies with SMA type 1?
Any discussion of prognosis needs a large asterisk labeled “treatment era matters.”
Historically, untreated SMA type 1 was frequently fatal in early childhood or led to permanent ventilation because respiratory muscles progressively weakened. Those historical statistics describe the natural history of untreated disease and should not automatically be applied to a baby receiving contemporary therapy.
Today, children diagnosed through newborn screening and treated before symptoms can achieve dramatically better survival and motor milestones. Some sit, stand, and walkabilities that were historically unexpected in classic type 1 SMA. Nevertheless, responses vary. Some children retain substantial weakness or require respiratory, feeding, mobility, or orthopedic support despite treatment.
Long-term data are still developing because many children receiving modern therapy are among the first generation to grow up in this new treatment era.
Can SMA type 1 be prevented?
The inherited genetic condition itself cannot currently be prevented after conception. However, people planning a pregnancy can consider SMA carrier screening.
If both partners are carriers, a genetic counselor can explain reproductive options, including prenatal diagnostic testing and assisted reproductive technologies. Carrier screening is not perfect, and a negative test can leave some residual risk, particularly because SMN1 genetics can be complex.
When should parents seek medical attention?
Parents should contact a pediatric healthcare professional promptly if a baby shows unexplained low muscle tone, unusually limited movement, loss of previously acquired abilities, persistent difficulty holding the head up, feeding or swallowing problems, weak crying, or breathing difficulty.
Emergency medical care is appropriate for significant trouble breathing, bluish coloration, episodes of choking with impaired breathing, severe lethargy, or other signs of acute respiratory distress.
Because early treatment can materially affect outcomes, suspected SMA is not something to place on the “we’ll mention it at the next routine visit” list.
Living with SMA type 1: What the experience can really look like
The following section summarizes common caregiver experiences reported in SMA clinical care and published family stories. It is not intended to represent one specific family or predict an individual child’s outcome.
For many families, the SMA journey begins with something surprisingly ordinary. Tummy time seems harder than it did for an older sibling. A baby’s legs do not kick much. Grandparents comment that the baby feels floppy when held. Feeding takes forever. None of those observations immediately announces, “This is a genetic neuromuscular disease,” so families diagnosed after symptoms appear often describe weeks of uncertainty before testing finally gives the problem a name.
Newborn screening produces a very different emotional experience. Parents may be holding a baby who looks perfectly healthy when they receive a call saying that the screening result suggests SMA. Instead of searching for an explanation for weakness, they suddenly must understand genetics, SMN2 copy numbers, drug mechanisms, insurance approvals, laboratory tests, and treatment decisions while simultaneously mastering the already demanding sport of keeping a newborn fed and asleep.
The first days after diagnosis can therefore feel like medical information arriving through a fire hose.
Families frequently learn that progress with SMA treatment is not always dramatic or immediate. A treatment does not necessarily produce a movie-scene transformation the following morning. Improvements may appear gradually: a stronger cry, better head movement, longer kicks, improved endurance during feeding, or eventually a developmental milestone that once seemed uncertain.
These apparently small changes can feel enormous. A parent of a child with SMA may celebrate five seconds of unsupported sitting with the enthusiasm another household reserves for a championship victory.
Clinical stories from major pediatric SMA programs illustrate how dramatically the treatment era has changed expectations. Children with type 1 who historically would not have been expected to sit independently have, after early disease-modifying treatment, gained motor abilities previously considered outside the classic type 1 trajectory. At the same time, other children continue to need wheelchairs, ventilatory assistance, feeding support, orthopedic treatment, or substantial help with daily activities.
Caregiving can also involve considerable logistics. Families may coordinate neurology appointments, physical therapy, respiratory equipment, feeding evaluations, laboratory monitoring, medication deliveries, insurance paperwork, and emergency plans for respiratory infections. Equipment that initially looks intimidatingcough-assist machines, suction devices, feeding pumps, positioning systemscan eventually become ordinary household technology.
Another recurring experience is learning not to judge a child’s abilities by muscle strength alone. Babies and children with SMA can be intensely curious and socially engaged even when their bodies make movement difficult. Families often adapt toys, switches, seating, communication methods, and play environments so physical limitations do not unnecessarily restrict learning or participation.
The emotional landscape is equally complicated. Parents may feel grief about the diagnosis and hope about treatment at the same time. They may worry about future complications while also enjoying perfectly ordinary moments: a favorite cartoon, a messy meal, a sibling argument, or the discovery that a toddler has developed very strong opinions about which pajamas are acceptable.
For families entering the SMA world today, perhaps the most important practical lesson is that old internet statistics do not tell the whole story. Historical natural-history data remain medically important, but the experience of a child diagnosed and treated in 2026 can be profoundly different from that of a child born before disease-modifying therapies were available.
That uncertainty cuts both ways. Modern treatments offer genuine reason for optimism, but no clinician can promise exactly which milestones an individual baby will achieve. The most useful approach is usually early specialist treatment, thoughtful supportive care, regular functional assessment, and attention to the child in front of the medical chartnot merely the label “SMA type 1.”
Conclusion
Spinal muscular atrophy type 1 is a serious genetic neuromuscular disorder caused primarily by abnormalities in both copies of the SMN1 gene. Insufficient SMN protein leads to progressive loss of motor neurons, causing muscle weakness that can interfere with movement, feeding, swallowing, coughing, and breathing.
What has changed most dramatically is the outlook. Newborn screening can identify SMA before obvious symptoms appear, and modern treatments can increase functional SMN protein or address the underlying genetic defect. Evidence increasingly shows that earlier treatment is associated with better motor outcomes, making rapid diagnosis and referral to an experienced SMA team critically important.
SMA type 1 has not suddenly become a simple disease. Many children still require multidisciplinary medical and supportive care, and outcomes vary considerably. Yet the modern SMA story is no longer adequately summarized by the grim natural-history statistics found in older references. Treatment has rewritten much of the scriptand researchers are still discovering how different the next chapters may become.
Note: This article is intended for general educational purposes and does not replace diagnosis or individualized treatment from a pediatric neurologist, neuromuscular specialist, genetic counselor, or other qualified healthcare professional.
Research note: Content was synthesized from current U.S. medical and regulatory information including NIH/MedlinePlus, NCBI GeneReviews and PubMed, HRSA newborn screening resources, FDA prescribing and approval information, ACOG, Johns Hopkins Medicine, Cleveland Clinic, Stanford Medicine Children’s Health, Children’s Hospital of Philadelphia, Muscular Dystrophy Association, Cure SMA, NORD, and related peer-reviewed evidence.
